Median number (MD) of annual and mean number of cumulative intravitreal anti-VEGF injections and non-injection visits stratified by year completed
| Patients and eyes with completed follow-up years | ||||||
| 1 | 2 | 3 | 5 | 7 | 10 | |
| MD (IQR) | MD (IQR) | MD (IQR) | MD (IQR) | MD (IQR) | MD (IQR) | |
| Intravitreal injections/year | 6 (5–8) | 6 (3–7) | 6 (3–7) | 6 (4–7) | 6 (3–7) | 5 (2–7) |
| Visits/year | 4 (3–4) | 3 (2–4) | 3 (2–4) | 3 (2–4) | 3 (2–4) | 3 (2–4) |
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
| Cumulative IVI count | 6.2 (2.1) | 12 (4.1) | 17 (5.7) | 28 (8.9) | 39 (12) | 54 (17) |
| Cumulative visit count† | 3.8 (1.2) | 7.0 (2.0) | 10 (2.6) | 16 (3.9) | 22 (4.8) | 29 (5.6) |
*At the end of each year.
†Non-injection visit.
anti-VEGF, antivascular endothelial growth factor; IVI, intravitreal injection.